The
corticosteroid budesonide and the rapid-onset, long-acting beta(2)-adrenoceptor agonist
formoterol have been combined into a single pressurized
metered-dose inhaler (pMDI) for use in patients with
chronic obstructive pulmonary disease (
COPD). Well designed 6- and 12-month clinical trials, twice-daily
budesonide/
formoterol pMDI 320 microg/9 microg effectively improved lung function in patients with moderate to very severe
COPD. The co-primary endpoints of adjusted mean morning predose forced expiratory volume in 1 second (FEV(1)) and 1-hour post-dose FEV(1) improved from baseline to a significantly greater extent with twice-daily
budesonide/
formoterol pMDI 320 microg/9 microg than with twice-daily placebo,
budesonide pMDI 320 microg and
formoterol dry powder inhaler 9 microg.
Budesonide/
formoterol pMDI was also associated with improvements from baseline in other measures of lung function,
COPD control (including the time to first
COPD exacerbation in the 12-month trial), symptoms and health status. These improvements were significantly greater than those observed with placebo and, for some endpoints, monotherapy with the individual components.
Budesonide/
formoterol pMDI was well tolerated in clinical trials in patients with
COPD. Its overall adverse event profile is consistent with the known tolerability profiles of
formoterol and
budesonide, and is generally similar to that with placebo.